Analytical reactivity of 13 commercially available rapid influenza diagnostic tests with H3N2v and recently circulating influenza viruses

Michael E. Bose, Amy Sasman, Hong Mei, Kate C. McCaul, William J. Kramp, Li-Mei Chen, Roxanne Shively, Tracie L. Williams, Eric T. Beck, Kelly J. Henrickson

Medical College of Wisconsin, Milwaukee, WI, USA. Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, US Department of Health and Human Services, Washington, DC, USA. Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA. Division of Laboratory Science, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA. Dynacare Laboratories, Milwaukee, WI, USA. Children’s Research Institute, Wauwatosa, WI, USA.

Correspondence: Kelly J. Henrickson, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA. E-mail: khenrick@mcw.edu

Accepted 26 February 2014. Published Online 3 April 2014.

Objectives Rapid influenza diagnostic tests (RIDTs) used widely in clinical practice are simple to use and provide results within 15 minutes; however, reported performance is variable, which causes concern when novel or variant viruses emerge. This study’s goal was to assess the analytical reactivity of 13 RIDTs with recently circulating seasonal and H3N2v influenza viruses, using three different viral measures.

Design Virus stocks were characterized by infectious dose (ID50) and nucleoprotein (NP) concentration, diluted at half-log dilutions, and tested with each RIDT and real-time RT-PCR.

Results Strong correlation was observed between NP concentration and RIDT reactivity; however, only weak correlation was seen with ID50 or C\text{t} values. Only four RIDTs detected viral NP at the lowest dilution for all influenza A viruses (IAV). Influenza A viruses not detected by more than one RIDT had lower NP levels. Of the 13 RIDTs, 9 had no significant differences in reactivity across IAV when compared to NP levels.

Conclusions Previous reports of RIDT performance typically compare reactivity based on ID50 titers, which in this study correlated only weakly with proportional amounts of viral NP in prepared virus samples. In the context of the strong correlation of RIDT reactivity with NP concentration, H3N2v was found to be as reactive as seasonal circulating IAV. While these findings may not reflect clinical performance of these RIDTs, measuring NP concentration can be useful in the future to assess comparable reactivity of available RIDTs, or to assess reactivity with newly evolving or emerging viruses.

Keywords Diagnostic, FDA, H3N2v, influenza, rapid.

Introduction

Rapid influenza diagnostic tests (RIDTs) are commonly used in clinical practice because they are simple to use and can provide results within 15 minutes. All RIDTs available in the USA during the 2012–13 season utilize lateral flow immunoassays with antibodies specific to the nucleoprotein of influenza A viruses (IAV) and influenza B viruses (IBV) for the rapid qualitative detection of each virus type. Currently available RIDTs rely on a visual colorimetric signal or require a reader to interpret reflectance or fluorescence. Previous reports note disparities between ID50 titers and RIDT reactivity with viral nucleoproteins from seasonal, swine, and avian IAV,\textsuperscript{1,2} while another report observed that low NP levels as measured by mass spectrometry were associated with reduced ranges of analytical reactivity for pandemic H1N1 (pH1N1) and human seasonal H3N2 viruses.\textsuperscript{3} With the emergence of the pH1N1 virus in humans, there was concern with the ability of available RIDTs to reliably detect this virus. During the early pandemic, RIDTs were reported to have reduced sensitivity, while later studies suggested otherwise.\textsuperscript{4–7}

In 2011, an influenza A variant virus was sporadically detected in human respiratory specimens. This variant carries the matrix gene from pH1N1 and the remaining genes from a triple reassortant North American swine H3N2 virus.\textsuperscript{8,9} While the total number of reported cases of H3N2 variant (H3N2v) in 2011 was low with only 12 cases, the 309 cases reported in 2012 and continued cases in 2013 (http://www.cdc.gov/flu/swineflu/h3n2v-case-count.htm) raise concerns
that this virus could spread more broadly in communities. As with the emergence of the pH1N1 virus, there are reports that some RIDTs may have reduced sensitivity for H3N2v, when measured against ID50 titer.

This study applied ID50, cycle threshold (Ct) values, and nucleoprotein (NP) measures of virus stock dilutions to evaluate the reactivity ranges of 13 FDA-cleared RIDTs with a selection of seasonal and H3N2v viruses.

Materials and methods

Viruses

Virus designations with stock concentrations are listed in Figure 1. Frozen aliquots of stocks quantified by chicken embryo infectious virus titer (EID50/ml) or MDCK tissue culture (TCID50/ml) received from the Influenza Division, WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza, Centers for Disease Control and Prevention, Atlanta, GA, USA (CDC), were used for all determinations.

Mass spectrometry

NP concentration (µg/ml) was measured by isotope dilution mass spectrometry as described for hemagglutinin and neuraminidase proteins. Virus stocks were enzymatically digested with trypsin and spiked with 13C- and 15N-labeled analogs of the NP target peptides (LIQNSITIER, LIQNSITIEK, and LIQNSLTIER for IAV and ALVDQVIGSR,

| Virus Strain (Subtype) | Measurements | Reactive results at each dilution |
|------------------------|--------------|----------------------------------|
|                         | ID50/ml      | NP (µg/ml) | Ct (10–1) | 10–1·0 | 10–1·5 | 10–2·0 | 10–2·5 | 10–3·0 | 10–3·5 | 10–4·0 |
| 1 A/California/07/2009(H1N1pdm) | 108·4 | 13·4 | 20·2 | 12 | 11 | 11 | 2 | 2 | 1 |
| 2 A/California/08/2009(H1N1pdm) | 109·2 | 6·0 | 19·0 | 13 | 12 | 4 | 1 | 1 |
| 3 A/Mexico/4108/2009(H1N1pdm) | 108·5 | 3·2 | 19·7 | 11 | 11 | 2 | 1 |
| 4 A/Minnesota/03/2011(H1N1pdm) | 108·9 | 0·7 | 21·1 | 9 | 3 | 1 |
| 5 A/New York/18/2009(H1N1pdm) | 108·7 | 10·5 | 21·1 | 13 | 12 | 9 | 2 | 1 |
| 6 A/South Carolina/02/2010(H1N1pdm) | 108·2 | 6·3 | 20·5 | 13 | 12 | 8 | 1 | 1 |
| 7 A/Brisbane/10/2007(H3N2) | 107·2 | 2·1 | 20·1 | 13 | 12 | 2 | 1 |
| 8 A/Montana/05/2011(H3N2) | 107·5 | 1·4 | 23·1 | 6 | 2 |
| 9 A/Perth/10/2010(H3N2) | 108·2 | 5·9 | 22·1 | 13 | 13 | 6 | 1 | 1 |
| 10 A/Perth/16/2009(H3N2) | 108·2 | 1·4 | 21·5 | 12 | 6 | 1 |
| 11 A/Victoria/361/2011(H3N2) | 108·2 | 11·4 | 18·7 | 13 | 13 | 11 | 2 | 1 | 1 |
| 12 A/Indiana/08/2011(H3N2v) | 107·3 | 1·4 | 21·5 | 10 | 5 | 2 |
| 13 A/Indiana/10/2011(H3N2v) | 1010·2 | 2·7 | 18·2 | 10 | 8 | 3 |
| 14 A/Kansas/13/2009(H3N2v) | 107·0 | 1·9 | 20·9 | 10 | 8 | 5 | 1 |
| 15 A/Minnesota/11/2010(H3N2v) | 109·2 | 3·0 | 19·1 | 10 | 8 | 2 |
| 16 A/Pennsylvania/14/2010(H3N2v) | 109·1 | 1·5 | 20·1 | 9 | 6 |
| 17 A/Pennsylvania/14/2010(H3N2v) | 109·1 | 1·5 | 20·1 | 9 | 6 |
| 18 A/West Virginia/06/2011(H3N2v) | 108·9 | 1·4 | 21·7 | 11 | 8 | 4 | 1 |
| 19 B/Brisbane/60/2008(Victoria-like) | 109·3 | 5·5 | 17·2 | 13 | 11 | 3 | 1 | 1 | 1 |
| 20 B/Nevada/03/2011(Victoria-like) | 108·2 | 2·7 | 17·5 | 13 | 12 | 5 | 2 | 2 |
| 21 B/Pennsylvania/05/2007(Victoria-like) | 108·0 | 6·5 | 17·0 | 13 | 10 | 2 | 1 |
| 22 B/Pennsylvania/03/2007(Yamagata-like) | 108·4 | 6·6 | 17·7 | 13 | 9 | 4 | 1 | 1 |
| 23 B/Pennsylvania/07/2007(Yamagata-like) | 108·2 | 6·0 | 16·8 | 13 | 9 | 2 | 1 |
| 24 B/Wisconsin/01/2010(Yamagata-like) | 108·2 | 5·4 | 18·1 | 13 | 7 | 1 | 1 | 1 |

Number of reactive kits at each dilution

13 9–12 4–8 1–3

Figure 1. Viruses used in this study, with measurements by TCID50/ml or EID50/ml, NP in µg/ml as determined by mass spectrometry, and the Ct value of the 10–1 dilution. Viruses 13, 15, and 18 were quantified by TCID50/ml (red numbering). All others were quantified by EID50/ml. Also shown is the number of reactive rapid influenza diagnostic tests results (at least 2/3 positive) for each influenza virus dilution. A maximum of 13 test kits could be positive for each dilution.
VVLPISIYAK, and SGATGVAIK for IBV). Reverse-phase separation of peptides and analysis by mass spectrometry were as described. Reverse-phase separation of peptides and analysis by mass spectrometry were as described. Publication with complete details of this method and applicability to a broader range of viruses is in process. Mass spectroscopy analysis was performed at the Division of Laboratory Science, National Center for Environmental Health, CDC.

**Virus dilution**

One virus stock was used each day with the real-time RT-PCR and all RIDTs described in Table 1. Each morning, a single virus stock was thawed and diluted in 0.9% saline (Sigma-Aldrich Company, St. Louis, MO), the only liquid medium compatible with all RIDTs used in this study. Virus stocks were thawed on ice and diluted in serial half-log-dilutions from $10^{-1}$ to $10^{-4}$. Each virus dilution was transferred into 200 µl aliquots and stored on ice or in the 4°C refrigerator until used that day.

**Real-time RT-PCR**

The CDC Influenza Virus rRT-PCR Diagnostic (Flu A&B) Panel (Influenza Reagent Resource, Manassas, VA, USA) was performed on each dilution as previously described. XY scatter plots of log10 dilution versus the corresponding C<sub>t</sub> value were generated (Microsoft Excel 2010, Microsoft Corp., Redmond, WA, USA). All 24 viral dilution series had a linear regression $r^2$ value above 0.95 (generally >0.99), assuring consistent dilution series for each virus. The C<sub>t</sub> values for the $10^{-1}$ dilution are used in analyses (see Figure 1), as dilution curves tended to deviate from linearity when C<sub>t</sub> values from the undiluted virus stock were included in the regression (data not shown).

**Rapid influenza diagnostic tests**

Testing with RIDTs and RT-PCR was performed between October and December 2012 at the Medical College of Wisconsin. Rapid influenza diagnostic tests are listed in Figure 2. Complete detailing of these RIDTs is available at http://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm#Table 2. Five of the RIDTs are CLIA-waived, categorized as simple laboratory examinations that have an insignificant risk of an erroneous result.

Positive and negative controls provided with each RIDT kit were tested upon receipt for each lot in every shipment. All aspects of the evaluation including diluent, swabs, and virus input were standardized. The manufacturer’s instructions for testing a swab specimen directly (without placing the swab in transport medium) were always followed (nasopharyngeal swab instructions were used for most RIDTs; throat swab instructions for the BD Directigen EZ Influenza A+B).

Following virus stock dilution, 50 µl of each dilution was placed into three 1.5-ml microcentrifuge tubes and held on ice. A sterile foam swab (Catalog # 25-1506-1PF, Puritan Medical Products Co. LLC, Guilford, ME, USA) was used to absorb each of the 50 µl samples in the microcentrifuge tubes and used as the input. Adjustments to this procedure were used when RIDT instructions required input with liquid suspensions of swab samples. For the 3M<sup>TM</sup> Rapid Detection Flu A+B test and BD Veritor for Liquid Samples, after absorbing the sample the swab was placed into a tube.

| RIDT                  | Flu A – H1N1pdm | Flu A – H3N2 | Flu A – H3N2v | Flu B | Viruses not reactive | Total no. of tests | No. of invalid tests | No. of false positives |
|-----------------------|-----------------|--------------|---------------|-------|----------------------|--------------------|----------------------|------------------------|
| Sofia Influenza A+B FIA | 6/6             | 6/6          | 6/6           | 6/6   | –                    | 513                | 4                    | 1                      |
| BD Veritor Flu A+B – for swab specimens | 6/6           | 6/6          | 6/6           | 6/6   | –                    | 444                | 0                    | 0                      |
| Xpect<sup>TM</sup> Flu A&B | 6/6             | 5/6          | 6/6           | 6/6   | 8                    | 420                | 0                    | 0                      |
| OSOM Influenza A&B    | 6/6             | 5/6          | 6/6           | 6/6   | 8                    | 417                | 0                    | 0                      |
| Alere Influenza A&B   | 6/6             | 5/6          | 6/6           | 6/6   | 8                    | 357                | 0                    | 0                      |
| Directigen EZ Flu A+B | 6/6             | 6/6          | 6/6           | 6/6   | –                    | 378                | 0                    | 0                      |
| BD Veritor Flu A+B – for liquid specimens | 6/6          | 6/6          | 6/6           | 6/6   | –                    | 381                | 6                    | 0                      |
| TRUFLU                | 5/6             | 5/6          | 6/6           | 6/6   | 8, 4                 | 411                | 0                    | 0                      |
| 3M<sup>TM</sup> Rapid Detection Flu A+B | 5/6           | 5/6          | 5/6           | 6/6   | 4, 8, 13             | 366                | 0                    | 0                      |
| QuickVue Influenza A+B | 6/6             | 6/6          | 2/6           | 6/6   | 14, 15, 16, 17       | 357                | 0                    | 0                      |
| BinaxNOW Influenza A & B | 6/6         | 5/6          | 4/6           | 6/6   | 8, 13, 17            | 357                | 0                    | 0                      |
| Status Flu A + B      | 4/6             | 6/6          | 1/6           | 6/6   | 3, 4, 14, 15, 16, 17, 18 | 405                | 0                    | 4                      |
| SAS FluAlert Influenza A; SAS FluAlert Influenza B | 3/6          | 4/6          | 0/6           | 6/6   | 1, 3, 4, 8, 10, 13, 14, 15, 16, 17, 18 | 264                | 0                    | 0                      |
containing 1 ml of UTM (Quidel Corporation, San Diego, CA, USA) and mixed prior to using the manufacturers’ specified volume input for these two RIDTs. BinaxNOW requires placing the swab in an elution solution (either purchased or substituted with 500 µl saline, used in this testing). Both FluAlert (SA Scientific, San Antonio, TX, USA) RIDTs are only indicated for nasal wash and aspirate samples. As the required sample input for this RIDT is 250 µl, we combined the 50 µl dilution sample with 200 µl of 0-9% saline. Even though this is a CLIA-waived test, the moderate complexity protocol was used due to multiple invalid results during quality control testing with the waived protocol. Kit-provided flocked swabs were used with the Status® Flu A+B test (Princeton Biomedical, Monmouth Junction, NJ, USA), as instructions do not allow for foam swabs used with other RIDTs.

After the study started, Quidel issued a recall of previously used Sofia FIA lots. At that point, 1 false-positive influenza B result was recorded with a negative control during the use of over 450 Quidel Sofia tests (Table 1). The manufacturer replaced remaining kits and no further influenza B false positives occurred with replacement kits. With the Status RIDT, four false positives for influenza B were observed: two in negative control replicates, one in a 10⁻¹ dilution of an A/Minnesotan03/2011 replicate, and one in a 10⁻¹ dilution of an A/Victoria/361/2011 replicate.

Statistical analyses

For analyses, the highest dilution reactive (HDR) was determined as the one in which two of the three replicates were positive for any one virus. Spearman’s rank correlation analyses between stock ID₅₀ titers, NP concentration, and 10⁻¹ dilution Cᵢ for each virus were used to assess the associations between these measures. A Spearman’s rank correlation was also performed comparing the mean HDR for all RIDTs to the stock ID₅₀ titers, NP concentration, and 10⁻¹ dilution Cᵢ for each virus. TCID₅₀ quantitations (three viruses) were omitted only from correlation analyses with ID₅₀ due to unverified comparability of TCID₅₀ and EID₅₀ methods. Any virus and RIDT combination with no reactivity in the 10⁻¹ dilution was not included in the correlation calculations; however, for subsequent analyses, the nominal value of the 10⁻⁰·₅ dilution was used. To compare virus groups for each RIDT, a log transformation was applied to normalize the variances of the reactivity measures before performing one-way ANOVAs. P-values between significantly different IAV groups for individual RIDTs were determined by Tukey’s honest significant difference test. All analyses were performed in Microsoft Excel 2010.

Results

Comparison of ID₅₀, Nucleoprotein, and RT-PCR Cᵢ measures

Figure 1 lists the ID₅₀, Cᵢ values, and NP concentration for the virus stocks. Correlation coefficients for the association between ID₅₀, NP concentration, and Cᵢ values across viruses were weak for ID₅₀ and Cᵢ versus NP (0.094 and −0.35) and moderate for ID₅₀ versus Cᵢ values (−0.75). When the viruses with TCID₅₀ quantitation were included, the correlation was stronger for ID₅₀ versus NP and was weaker for ID₅₀ versus Cᵢ values, but had no impact on interpretation of the results.

RIDT results

Figure 1 shows the number of tests that were positive in at least two of three replicates at each dilution for each of the 24 viruses. All 13 RIDTs were reactive with seven of the 18 IAVs and all six of the IBVs. Only four RIDTs (Sofia, both Veritors, Directigen) were reactive with all IAVs in the initial dilution (10⁻¹) tested (Figure 2 and Table 1). The remaining RIDTs were not reactive with at least one IAV at any dilution tested. Notably, nine RIDTs detected all pH1N1 viruses, six RIDTs detected all H3N2 viruses, and eight RIDTs detected all H3N2v viruses in the 10⁻¹ dilution. One RIDT (SAS FluAlert Influenza A test and Influenza B test, which are separate test units, but boxed together in one kit) had reactivity in only seven IAVs (none in the H3N2v group, three in the pH1N1, and four in the H3N2 seasonal group).
The reactivity of other RIDTs ranged from detection of 11 (Status) to 17 (X/Pect, OSOM, Alere) IAVs in the 10⁻¹ dilution (Table 1).

For IAVs, patterns of reactivity are variable across all virus groups for both individual viruses (Figure 1) and for individual RIDTs (Figure 2). While we chose to score a dilution as reactive if 2 of 3 replicates at that dilution were positive, the majority of RIDTs yielded 3 of 3 positives at the highest dilution scored as reactive, and 0 of 3 positive results at all higher dilutions. There were seven occurrences for which an RIDT was scored reactive with 2 of 3 replicates positive. A total of 20 occurrences had only 1 of 3 positive replicates for any one RIDT in the next dilution beyond the HDR. The majority of these (15 of 20) were with RIDTs interpreted by automated readers from both fluorescent (Sofia, 3M) and reflectance (Veritor) signals. These readers may discriminate subtle differences in reaction intensity that are not apparent in visual reads.

Differences in mean stock NP concentrations between IAV that were reactive in all RIDTs and those that were not reactive in more than one RIDT suggest a link between NP concentration and test reactivity (Table S1). Those IAVs not reactive in more than one RIDT had a mean stock NP concentration of 1-9 µg/ml (range: 0.7–3.2), whereas the mean for all IAVs was 4.3 NP µg/ml (range: 0.7–13.4 µg/ml). ID₅₀ titer ranges were similar and overlapped considerably across each of the virus groups as did the Ct value ranges at the 10⁻¹ dilution for the IAVs. The range of stock NP concentrations was narrower for IBVs, yet HDRs varied widely across RIDTs.

Figure 3 shows the mean log HDR for each virus plotted versus stock log NP, stock log ID₅₀, and 10⁻¹ dilution Ct values. For IAV, the correlation is strong (r = 0.86) between stock NP concentration and the mean HDR for all test kits. On the other hand, correlation between stock ID₅₀ and HDR is practically zero (r = 0.015) and weak between Ct values and HDR (r = 0.24).

As NP concentration versus mean HDR had a strong association across all RIDTs for IAV, the mean NP (for all viruses in a virus group) was plotted against each RIDT (Figure 4). ANOVAs showed no significant difference (P-value >0.05) between any of the IAV groups for nine individual RIDTs. These nine RIDTs include those reactive with all IAVs (n = 4). While individual RIDTs showed some variation between IAVs, no individual IAV subtype was significantly less reactive across all RIDTs, when compared with NP concentrations by ANOVA as shown in Figure 4 with four exceptions. The FluAlert RIDT was apparently less reactive with pH1N1 and H3N2v (only 3 and 0, respectively) than with H3N2 viruses (four reactive). This particular RIDT, however, was less reactive for H3N2 than other RIDTs when compared to NP levels detected as shown in Figure 4. Additionally, this RIDT failed to react with the pH1N1 virus with the highest stock NP measure (13.4 µg/ml for A/California/07/2009). Status was also less reactive with pH1N1 and H3N2v than with H3N2 viruses (4 and 1 reactive versus all 6, respectively) yet was similar to other RIDTs in the calculated NP reactivity for H3N2 viruses. QuickVue was less reactive with H3N2v than with either the pH1N1 or H3N2 group (only 2 of 6 H3N2v viruses were reactive, while all other IAVs were reactive). Note: Reduced reactivity with H3N2v viruses for QuickVue and FluAlert was also observed in a previous study.¹ TRUFLU, on the other hand, was more reactive with the H3N2v group than with the pH1N1 group (6 reactive with H3N2v versus 5 with pH1N1) yet no statistical difference was found between pH1N1 and H3N2

Figure 3. Scatter plots showing the mean log highest dilution reactive (HDR) across all rapid influenza diagnostic tests for each virus tested against (A) the log stock NP concentration, (B) the log stock ID₅₀, and (C) the 10⁻¹ dilution Ct value. The black line shows the linear regression trend line and the black dotted lines show the 95% confidence interval, along with equations and R² values for each trend line. Only viruses quantified by EID₅₀/ml were used for the trendline in B.
Reactivity of 13 RIDTs with influenza viruses

Figure 4. Graph showing the mean NP concentration at the highest dilution reactive for each of the virus groups (pH1N1, H3N2, H3N2v, and influenza B) for each of the rapid influenza diagnostic tests (RIDTs). * indicates that an influenza A viruses (IAV) group is significantly different from other IAV groups for that RIDT based on Tukey’s HSD test. The QuickVue test was significantly less reactive with H3N2v than with pH1N1 and H3N2. The Status test was significantly more reactive with H3N2 than with pH1N1 or H3N2v. The Flu Alert test was significantly more reactive with H3N2 than with pH1N1 (H3N2v could not be statistically evaluated). The TRU FLU test was significantly more reactive with H3N2v than with pH1N1. A † represents situations in which an RIDT was reactive with 3 or less viruses in a group. CLIA indicates that an RIDT is CLIA-waived.

Conclusions

The primary goal of this study was to determine whether RIDTs are as reactive with H3N2v IAVs as with other influenza viruses. Aggregate reactivity results for all RIDTs with each virus in Figure 1 suggest reduced reactivity with H3N2v when shown by dilution. However, further analysis referencing stock NP values supports that the majority of RIDTs were not less reactive with H3N2v virus NP than with other IAV-NP. In this evaluation, H3N2 and pH1N1 as well as H3N2v viruses with low stock NP concentrations were more likely to be non-reactive or to have reduced ranges of reactivity (and lower HDRs) in RIDTs. Notably, the H3N2v virus stocks had the lowest NP concentrations as a group, which could be a factor with reduced sensitivity in clinical practice if these viruses also produce less NP during human infection.

The strong correlation of the virus stock NP concentrations with mean HDRs in this evaluation is not unexpected given that all of the RIDTs are designed to detect viral nucleoprotein using different antibodies to capture and detect influenza A and B viruses, and this association was also observed in a previous study. The poor correlation of these IAV stock NP concentrations with ID$_{50}$ titers, a virus measure known for variability between laboratories and methods, warrants caution with assessing RIDT analytical reactivity with propagated influenza viruses characterized solely by ID$_{50}$ titers.

In this study, the BD Veritor RIDT for liquid specimens (e.g., swab in transport media) showed a decrease in reactivity when compared to the Veritor RIDT for swab specimens (tested directly). Previous testing with an RIDT using two sets of virus samples (50 µl adsorbed onto a swab and 50 µl added to 1 ml diluent prior to testing) showed a consistent decrease in reactivity for the set added to diluent (data not shown). A major advantage with RIDTs is the rapid time to results (if specimens are tested at the time of collection); placing swabs into transport media for RIDT may offset the benefit with rapid results if NP levels are lowered by dilution.

Although the correlation between NP concentrations and IAV reactivity is strong ($r^2 = 0.86$) in this study, it is unable to explain all of the variability in reactivity due to other potentially contributing factors. Such factors can include proprietary differences between individual RIDTs, sequence variations affecting epitope-binding sites, or differences in virus replication properties within infected host or culture cells and the potential for multiple virus quasispecies. Observations from this study, specifically that the (A/Montana/05/2011) virus with the lowest NP concentration was not reactive in the least number of RIDTs and (A/California/07/2009) virus with the highest NP concentration was not reactive in all of the RIDTs, suggest that there must be factors other than NP concentration contributing to reactivity. Furthermore, several RIDTs showed significant differences in reactivity between IAV groups, suggesting that antibody design may not be optimal for all IAV and amino acid variations between IAV groups could be a factor. A previous report explored the phylogenetic relationship between variant IAVs and seasonal IAVs and suggested that amino acid changes in a target epitope region could hypothetically reduce reactivity.

These findings are limited by the use of specific viruses, propagated under conditions that can influence ID$_{50}$ titers and relative $C_t$ values of harvested influenza viruses, as well as NP levels. Only six individual viruses comprised each influenza virus group as representative of each type or subtype. The dependency of the strong correlation with NP
levels on virus sourcing, growth conditions, and other stock propagation variables requires further research. In addition, the assumption that reactivity of a single RIDT should be consistent across IAV groups as long as antibody recognition and amounts of influenza NP are similar needs to be verified.

In conclusion, RIDTs are generally as reactive with H3N2v as with other IAVs even though differences in reactivity were observed between IAVs (seasonal or variant) for individual RIDTs. Our observation that H3N2v viruses as a group produced less NP in virus culture may be indicative of their growth in mammalian cells. Further characterization of these viruses in both virus culture and respiratory samples would be important for better understanding of these observations, for improving RIDT performance, and for use of RIDTs in clinical practice. This evaluation reinforces that negative RIDT results are more likely when any virus samples have low NP concentrations, regardless of ID50 titers or Ct values. Furthermore, performance estimates from either analytical or clinical studies may vary by the nature of the virus, as well as by specimen collection factors that optimize the amounts of viral NP sampled. Additional research is needed to determine ranges of NP concentrations in clinical specimens with different influenza A and B viruses or to verify that NP concentrations from an in vitro propagated virus reflect replication properties of the virus in host cells. Regardless, a standardized mass spectrometric method for directly measuring nucleoprotein levels in analytical virus preparations could offer an appropriate benchmark for comparing the reactivity of RIDTs, or assessing reactivity with newly evolving or emerging influenza viruses.

Addendum

M. E. Bose contributed to data analysis and interpretation and manuscript preparation. A. Sasman contributed to the RIDT, data compilation, and manuscript preparation. H. Mei and K. McCaul performed the RIDT and data compilation. W. Kramp and R. Shively contributed to the concept and design of the study, data analysis and interpretation, and manuscript preparation. E. T. Beck and K. J. Henrickson contributed to the concept and design of the study and manuscript preparation. L. Chen prepared the viruses used in this study. T. L. Williams managed the isotope dilution mass spectrometry work with NP quantitation and experts from the Influenza Division, NCIRD, CDC, who participated in designing and reviewing the study. We also thank Aniko Szabo, Ph.D., from the Medical College of Wisconsin’s Division of Biostatistics for assistance with the statistical analyses.

Acknowledgements

This study was supported by the U.S. Department of Health and Human Services (HHS), the office of Assistant Secretary for Preparedness and Response (ASPR) under Contract No. HHSO100201000010. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Department of Health and Human Services or its components. CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel, Influenza A/B Typing Kit (IVD) (Catalog No. FluIVD03-1), FR-813, and the influenza viruses used in this study were obtained through the Influenza Reagent Resource, Influenza Division, National Center for Immunization and Respiratory Diseases, CDC. We thank the Division of Laboratory Science, National Center of Environmental Health, CDC, for the mass spectrometry work with NP quantitation and experts from the Influenza Division, NCIRD, CDC, who participated in designing and reviewing the study. We also thank Aniko Szabo, Ph.D., from the Medical College of Wisconsin’s Division of Biostatistics for assistance with the statistical analyses.

References

1 Balish A, Garten R, Klimov A, Villanueva J. Analytical detection of influenza A(H3N2)v and other A variant viruses from the USA by rapid influenza diagnostic tests. Influenza Other Respir Viruses 2012; 6:491–496.
2 Baas C, Barr I, Fouchier R, Kelso A, Hurt A. A comparison of rapid point-of-care tests for the detection of avian influenza A(H7N9) virus, 2013. Euro Surveill 2013; 18:20487.
3 Centers for Disease Control and Prevention. Evaluation of 11 commercially available rapid influenza diagnostic tests—United States, 2011–2012. MMWR Morb Mortal Wkly Rep 2012; 61:873–876.
4 Centers for Disease Control and Prevention. Evaluation of Rapid Influenza Diagnostic Tests for Detection of Novel Influenza A (H1N1) Virus — United States, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:826–829.
5 Drekel JF, Helmer A, Kirberg H et al. Poor clinical sensitivity of rapid antigen test for influenza A pandemic (H1N1) 2009 virus. Emerg Infect Dis 2009; 15:1662–1664.
6 Kok J, Blyth CC, Foo H et al. Comparison of a rapid antigen test with nucleic acid testing during cocirculation of pandemic influenza A/H1N1 2009 and seasonal influenza A/H3N2. J Clin Microbiol 2010; 48:290–291.
7 Vasoo S, Stevens J, Singh K. Rapid antigen tests for diagnosis of pandemic (Swine) influenza A/H1N1. Clin Infect Dis 2009; 49:1090–1093.
8 Centers for Disease Control and Prevention (CDC). Swine-origin influenza A (H3N2) virus infection in two children—Indiana and Pennsylvania, July-August 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1213–1215.
9 Nelson MI, Vincent AL, Kitikoon P, Holmes EC, Gramer MR. Evolution of novel reassortant A(H3N2) influenza viruses in North American swine and humans, 2009–2011. J Virol 2012; 86:8872–8878.
10 Centers for Disease Control and Prevention (CDC). Update: influenza activity - United States and worldwide, May 20-September 22, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:785–789.
11 Lindstrom S, Garten R, Balish A et al. Human infections with novel reassortant influenza A(H3N2)v viruses, United States, 2011. Emerg Infect Dis 2012; 18:834–837.
12 Centers for Disease Control and Prevention (CDC). Evaluation of rapid influenza diagnostic tests for influenza A (H3N2)v virus and updated case count—United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:619–621.
13 Williams TL, Luna L, Guo Z et al. Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 2008; 26:2510–2520.

14 Williams TL, Pirkle JL, Barr JR. Simultaneous quantification of hemagglutinin and neuraminidase of influenza virus using isotope dilution mass spectrometry. Vaccine 2012; 30:2475–2482.

15 Shu B, Wu KH, Emery S et al. Design and performance of the CDC real-time reverse transcriptase PCR swine flu panel for detection of 2009 A (H1N1) pandemic influenza virus. J Clin Microbiol 2011; 49:2614–2619.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Table S1. Average measurement by virus group.